Valeant confirms it's in talks to potentially sell Salix stomach drug business

Valeant confirms it's in talks to potentially sell Salix stomach drug business


Valeant Pharmaceuticals said Tuesday it's in discussion that may lead to the sale of its core stomach drug business Salix. The comment was issued in response to published reports that the drugmaker is in advanced talks to sell Salix Pharmaceuticals Ltd. in order to trim its hefty US$30-billion debt load.



from Biotech News